SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major focal point for traders due to its recent surge in social media volume and discussion surrounding its post-quantum security features. Community members remain polarized, with many debating the impact of institutional-grade infrastructure upgrades and potential regulatory shifts while long-term holders focus on accumulation during significant price volatility.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as the community eagerly awaits definitive biomarker data and regulatory updates regarding an accelerated approval pathway for its ALS candidate, CNM-Au8. Investors are closely monitoring upcoming conference presentations and regulatory milestones, balancing high-conviction long-term sentiment against volatility driven by short interest and recent insider selling activity.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is experiencing heightened volatility and intense community debate as it tests critical support levels around 60k-65k, with traders closely monitoring technical formations like bear flags and head-and-shoulders patterns. While some bulls are looking for a reclaim of key resistance zones to trigger a long-term uptrend, many participants remain cautious, pointing to equity market weakness and potential liquidity risks that could lead to further downside tests.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently a focal point for the community due to major structural updates like Mission 70aimed at reducing token inflationand increasing adoption through sovereign subnets in regions like Switzerland and Pakistan. While some users remain skeptical due to historical volatility and the project's long-term performance, many community members are highlighting the real-world utility of platforms like Caffeine.ai and the growing number of canisters as indicators that the network's fundamentals are strengthening for a future recovery.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is capturing significant attention as the firm integrates advanced AI models to automate compliance roles, while simultaneously navigating heightened market scrutiny over its past ties to Jeffrey Epstein and recent leadership resignations. The stock is experiencing intense volatility as investors weigh these corporate headwinds against the firm's strategic expansion into private credit and asset management.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is experiencing significant momentum following a major $2.4 billion power infrastructure contract, with community discussions largely focused on its role in providing essential energy solutions for AI data centers. The stock is a primary focal point for investors tracking related holdings like B. Riley (RILY) and Applied Digital (APLD), as participants debate the impact of institutional backing and the potential for a long-term valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.</li><li>The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.</li><li>Korsana expects the financing round to close immediately prior to the proposed merger.</li></ul>Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Korsana Secures $380M In Commitments To Support Merger</h2>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.The company expects the financing round to close immediately prior to the proposed merger.Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.<h2 class="st-heading-2">What Does Korsana Do?</h2>Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.<a href="https://stocktwits.com/symbol/CYCN">CYCN stock</a> is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ipm-bcg-hubc-stocks-top-premarket-gainers-april-1-2026/cZ7H1jsRInn">IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

Cyclerion stated that it has entered into a definitive merger agreement with Korsana Therapeutics in an all-stock transaction.

Equity

Should Fidelity Nasdaq Composite Index ETF (ONEQ) Be on Your Investing Radar?

<ul class="summary-bullets"><li>SMX said that its latest amendment to its equity line of credit (ELOC) agreement has increased to $250 million.</li><li>The extended capital visibility will give the company the ability to maintain continuity in planning and execution, it said.&nbsp;</li><li>The company also said that since 2023, it has demonstrated its ability to repeatedly secure capital, showing proof of execution.</li></ul>Shares of SMX (Security Matters) PLC rallied over 129% on Friday after the company announced that it has extended its capital runway into 2028.SMX said that its latest amendment to its equity line of credit (ELOC) agreement has been increased from $116 million announced in December to $250 million, which has given it another 22 months of capital buffer.The extended capital visibility will give the company the ability to maintain continuity in planning and execution, it said.The capital “shapes partner confidence, deal velocity, and strategic discipline in ways the market usually recognizes only after the fact,” the company said.<h2 class="st-heading-2">Capital Usage</h2>SMX said that by extending its capital runway, it has reduced the pressure that usually compresses timelines and distorts strategy for small-cap firms.The company said the capital visibility is important due to the nature of the verification infrastructure platform it is building across physical materials, global supply chains, and regulatory systems.The company said that such platforms do not scale quickly or linearly, often requiring parallel development, coordination across partners, and time for validation and integration. The capital timeline extension better equips it for this.SMX also said that since 2023, it has demonstrated its ability to repeatedly secure capital, showing proof of execution.As SMX enters 2026, the company said its focus has shifted from exploration to deployment and conversion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMX">SMX shares</a> jumped from ‘bearish’ to ‘extremely bullish’ in the past 24 hours.Meanwhile, message volumes surged from ‘extremely low’ to ‘high’ levels.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_06_at_11_44_55_PM_png_3742aa9c2c.webp" alt="Screenshot 2026-02-06 at 11.44.55 PM.png" width="1270" height="165"></figure>&nbsp;One bullish user said that the capital runway till 2028 indicates that the company has ‘massive deals’ coming up.<stembedurl>https://stocktwits.com/SaySomethingNice/message/644303690</stembedurl>&nbsp;Another bullish user said this could be the start of a multi-week run, with the shares likely to go up to $400 again.<stembedurl>https://stocktwits.com/RyanTheScammer2/message/644301795</stembedurl>&nbsp;Shares of SMX are currently trading around $17 at the time of writing. SMX shares were at $400 levels in May 2025 before a series of reverse stock splits.SMX stock lost almost all its value in the past year, declining about 99.80%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/reddit-just-posted-strong-q4-results-so-why-are-some-analysts-lowering-targets/cZbFlItR4FK">Reddit Just Posted Strong Q4 Results — So Why Are Some Analysts Lowering Targets?</a>&nbsp;

 In this photo illustration, the SMX (Security Matters) logo is seen displayed on a smartphone screen.

SMX Shares Rallied Over 129% Today — Here’s Why

SMX (Security Matters) said on Friday that it has extended its capital runway into 2028. 

<ul class="summary-bullets"><li>The reverse split will take effect at the opening of trading on January 20.</li><li>Post the reverse split, outstanding Class A shares will be reduced to around 1.5 million from 88.6 million.</li><li>Shareholders had approved a reverse split between 1-for-2 and 1-for-200 on Mar. 14, 2025.</li></ul>Bit Origin (BTOG) shares slumped 32% on Thursday to their lowest in nearly nine months after the crypto mining firm announced a 1-for-60 reverse stock split of both its Class A and Class B shares.The reverse split will take effect at the opening of trading on January 20, with Class A shares continuing to trade on the Nasdaq Capital Market under the same ticker, the company said.This comes after shareholders approved a reverse split between 1-for-2 and 1-for-200 on Mar. 14, 2025, giving the board authority to set and implement the final ratio at any time before Mar. 14, 2026. The action is intended to maintain the stock’s compliance with Nasdaq’s listing requirements by meeting the $1 minimum bid price requirement.Once implemented, every 60 outstanding shares will be consolidated into one share, reducing the outstanding Class A shares from about 88.6 million to around 1.5 million and the outstanding Class B shares from 768,000 to 12,800.“While the Reverse Stock Split is intended to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), the Company cannot assure that it will be able to regain or maintain compliance with Nasdaq’s continued listing standards,” said Jinghai Jiang, Chairman and Chief Executive Officer of Bit Origin.In late August last year, Bit Origin received a notice from Nasdaq’s Listing Qualifications Department granting the company an additional 180-day extension, pushing its compliance deadline to Feb. 16, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/BTOG">BTOG stock</a> remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/BTOG_jpg_8537f72b4f.webp" alt="BTOG.jpg" width="934" height="100"></figure>One user had already anticipated the reverse split update.<stembedurl>https://stocktwits.com/Rosedale5/message/641799428</stembedurl>The company said that as of August 11, 2025, it had around 70.5 million Dogecoin (DOGE) holdingsRead also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-glxy-stock-rally-10-percent-today/cmU1pCqR4JB">GLXY Stock Rallied 10% Today – What Are The Two Factors At Play?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

BTOG Stock Tanks Over 30% — What Drove Shares To A Nearly Nine-Month Low?

The crypto mining firm’s board approved a 1-for-60 reverse stock split of both its Class A and Class B shares in order to maintain compliance with Nasdaq’s listing requirements.

<ul class="summary-bullets"><li>Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared, the company said.</li><li>he 78-year-old patient received a total of 17 treatment cycles, and completed 12 months on the study.</li><li>The company added that the trial has moved into Phase 2A, where Bria-OTS is being tested alongside an immune checkpoint inhibitor.</li></ul>Shares of BriaCell Therapeutics Corp. (BCTX) surged more than 50% on Tuesday after the clinical-stage biotechnology company announced a ‘durable and sustained complete resolution’ of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.BriaCell said the patient was the first enrolled in its Bria-OTS clinical study and had previously failed multiple lines of treatment. Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared. The response was first seen at two months and has since been confirmed at four, six, and now eleven months.The 78-year-old patient received a total of 17 treatment cycles, completed 12 months on study, and continues to be monitored in survival follow-up. BriaCell noted that the Phase 1 dose-escalation portion of the trial has been completed successfully.The company said the trial has now moved into Phase 2a, where Bria-OTS is being tested alongside an immune checkpoint inhibitor to potentially improve outcomes for patients with advanced breast cancer.“These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform. Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options,” said William V. Williams, BriaCell’s President and CEO.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’, accompanied by ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/BCTX">BCTX</a> was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/BCTX_jpg_ca990928c1.webp" alt="BCTX.jpg">One bullish user expects the stock to touch $20 today. It is currently at $11.5.<stembedurl>https://stocktwits.com/TommyDel/message/641632538</stembedurl>Another user observed $11 as a key buying zone.<stembedurl>https://stocktwits.com/NoobFriendly/message/641632355</stembedurl>However, the stock has been under heavy selling pressure over the past year, declining more than 87%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-alb-stock-rising-premarket/cmUXI0pR44w">ALB Stock Garners Retail Attention As Lithium Bulls Return</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did BCTX Stock Surge 50% Today?

The biotechnology company announced a complete recovery of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.

Why Did BCTX Stock Surge 50% Today? 

<ul class="summary-bullets"><li>SMX said that it entered 2026 fully-funded through the first quarter as it focuses on expanding its Plastic Cycle Token.</li><li>SMX had said it had expanded globally through partnerships and pilots.</li><li>Most recently, the company said it aims to fix inefficient tracking of cannabis by embedding its invisible molecular identifier directly into the packaging.</li></ul>SMX (Security Matters) PLC (SMX) shares surged over 103% in Wednesday’s morning trade even as retail traders debated a massive upside potential on the stock.Some retail traders expect the company’s share price to surge back up to $490 levels. Shares of SMX were trading around $39.3 at the time of writing.<h2 class="st-heading-2">Plastic Cycle Token Momentum</h2>SMX said earlier this week that it has entered 2026 fully-funded through the first quarter. The company is focused on expanding its Plastic Cycle Token. It is investing in rolling out its molecular marking and material verification technologies, strengthening its digital platform, and driving real-world adoption across global supply chains.In 2025, SMX said it had expanded globally through partnerships and pilots, proving its technology in real-world industrial settings and demonstrating its ability to scale beyond plastics into multi-material verification.Most recently, the company said it aims to fix inefficient tracking of cannabis by embedding its invisible molecular identifier directly into the packaging, creating a permanent, tamper-proof identity that travels with the product from cultivation to retail. The same technology also applies to food packaging and recycled plastics, it said.Earlier this month, SMX also <a href="https://stocktwits.com/news-articles/markets/equity/why-is-smx-stock-gaining-today/cmxVGkoRE61">announced</a> an expansion of its industrial rubber traceability platform with the addition of latex and rubber glove tracing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SMX stock jumped to ‘extremely bullish’ from ‘bullish’ territory a day ago while message volumes went to ‘high’ from ‘normal’ levels.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_07_at_11_19_08_PM_png_8265190daa.webp" alt="On Stocktwits, retail sentiment around SMX stock jumped to ‘extremely bullish’ from ‘bullish’ territory a day ago while message volumes went to ‘high’ from ‘normal’ levels." width="1273" height="162"></figure>One bullish user predicted the stock may go up to about $75.<stembedurl>https://stocktwits.com/SaySomethingNice/message/641099605</stembedurl>&nbsp;Another user contemplated whether it would reach its peak of $490 from a month ago.<stembedurl>https://stocktwits.com/erb71/message/641100211</stembedurl>&nbsp;<a href="https://stocktwits.com/symbol/SMX">Shares of SMX</a> were down over 99% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/nuvve-stock-in-focus-as-it-soars-over-78-percent-what-are-retail-investors-saying/cmxz322R42g">Nuvve Stock In Focus As It Soars Over 78% — What Are Retail Investors Saying?</a> &nbsp;

SMX Shares Double On Plastic Cycle Token Optimism — How Much More Upside Does Retail See?

Some retail traders expect SMX (Security Matters) share price to surge back up to $490 levels. 

<ul class="summary-bullets"><li>Markets extended a strong multi-year bull run, with the S&amp;P 500 posting solid double-digit gains and leadership concentrated in tech and communication services.</li><li>Retail traders remain divided, with roughly 40% expecting flat or negative year-end returns despite the market’s recent rebound.</li><li>Strategists see earnings growth, AI adoption, and resilient economic growth supporting 2026 upside.</li></ul>The futures market is yet to react significantly to the inflation reading. The CME FedWatch Tool, based on futures traders' expectations, still shows more than 75% odds of a pause at the January meeting. Economists, though positive about the Federal Reserve lowering rates further next year, were divided on whether a reduction will materialize in January.Where does this all leave the market, which is now in its fourth year of a bull run? Will Santa arrive on Wall Street on time to give the market the typical year-end lift? Will 2026 prove to be another bumper year for stocks?For the unversed, a Santa rally is a calendar effect in the stock market that drives sustained upside in the final five sessions of a year and the first two sessions of the following year. So, it starts on the 24th of this month, an abbreviated session ahead of the Dec. 25 Christmas holiday, and runs through Jan. 5.&nbsp;Historical trends prove that:<figure class="image"><img style="aspect-ratio:519/245;" src="https://news.stocktwits-cdn.com/4ee6dbb33419f5d505fe4641cde8e32b_6cb09028aa.webp" alt="4ee6dbb33419f5d505fe4641cde8e32b.webp" width="519" height="245"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;Source: Sevens Report via Investing.com&nbsp;<h2 class="st-heading-2">Market Check-In</h2>After the 2022 inflation-driven economic uncertainty drove the market into bear territory, it hit a bottom in October before bouncing back strongly.<h4 class="st-heading-4" style="text-align:center;">&nbsp;S&amp;P 500 Returns&nbsp;</h4><figure class="table" style="width:42.48%;"><table class="ck-table-resized"><colgroup><col style="width:27.81%;"><col style="width:72.19%;"></colgroup><tbody><tr><td>Year</td><td>Annual Returns</td></tr><tr><td>2025 (YTD)</td><td>+15.2%</td></tr><tr><td>2024</td><td>+23.3%</td></tr><tr><td>2023</td><td>+24.2%</td></tr><tr><td>2022</td><td>-19.4%</td></tr></tbody></table></figure>Among the 11 S&amp;P 500 sectors, communication services and IT have outperformed this year, with gains of&nbsp;more than 20%.&nbsp;<h4 class="st-heading-4" style="text-align:center;">S&amp;P 500 Sectors’ YTD Returns</h4><figure class="table" style="width:42.91%;"><table class="ck-table-resized"><colgroup><col style="width:71.47%;"><col style="width:28.53%;"></colgroup><tbody><tr><td>Sectors</td><td>Returns</td></tr><tr><td>Communication Services</td><td>+30.0%</td></tr><tr><td>IT</td><td>+20.6%</td></tr><tr><td>Industrials</td><td>+16.9%</td></tr><tr><td>Utilities</td><td>+13.2%</td></tr><tr><td>Financials</td><td>+12.5%</td></tr><tr><td>Healthcare</td><td>+11.4%</td></tr><tr><td>Materials</td><td>+7.4%</td></tr><tr><td>Consumer Discretionary</td><td>+7.2%</td></tr><tr><td>Consumer Staples</td><td>+2.6%</td></tr><tr><td>Energy</td><td>+2.5%</td></tr><tr><td>Real Estate</td><td>-0.9%</td></tr></tbody></table></figure>&nbsp;Indices, representing different market class categories, have had a solid run this year, although the broader tech sector and the narrower non-financial tech categories have been outperforming slightly.<img src="https://news.stocktwits-cdn.com/Market_YTD_Performance_png_3f6ee6c7e9.webp" alt="Market YTD Performance.png">Source: Koyfin<h2 class="st-heading-2">Retail Hopes But Stays Skeptic</h2>Not all retail traders are convinced that Santa will work his magic on Wall Street.&nbsp;An ongoing Stocktwits poll asking users about their expectations for the S&amp;P 500's potential return in the second half of December showed that nearly 40% of retail traders are bracing for either a flat or negative performance. A little over 60% expect the market to end the year with a gain.<figure class="image"><a href="https://stocktwits.com/discussions/what-do-you-expect-the-sp-500s-total-return-to-be-in-the-second-half-of-december/639317564"><img style="aspect-ratio:725/608;" src="https://news.stocktwits-cdn.com/S_Tpol_png_f5aa234af8.webp" alt="STpol;.png" width="725" height="608"></a></figure>It is worth noting that many of the votes were cast before the November inflation report was released on Thursday. On the polls timeline, a bearish user wrote, “The market is way overvalued.”His views aligned with those of NYSU Stern School of Business Finance and Economics Professor Aswath Damodaran, famously known as the “Dean of Valuation”. In an interview with CNBC last week, Damodaran said:<blockquote>“I’m not sure the remaining 493 [of the S&amp;P 500 stocks] are bargains relative to the Mag-7. They looked richly priced to me as well.”</blockquote><h2 class="st-heading-2">Inflation Adds Spring To Santa’s Steps</h2>The November inflation report showed a cool-off in the annual inflation rate to 2.7% from 3.1% in&nbsp; October. The yearly rate of core inflation also slowed to 2.6% from 3%. But economists do not see a smooth downward trend in inflation.Commenting on the inflation data, Northlight Asset Management Chief Investment Officer Chris Zaccarelli said the November data was only one month’s figure and will likely fluctuate in the coming months.<blockquote>“But the main concern of Fed officials who are reluctant to keep cutting is that inflation is persistently high and won’t come down if they keep lowering interest rates, and at this point, that doesn’t look like it’s the case.”</blockquote>LPL Financial Chief Economist Jeffrey Roach also expects bumpy inflation readings in the next few months but expects it to drop to 2.5% by the year-end, allowing the Federal Reserve to cut rates a few times next year.Fund manager Louis Navellier hoped the Santa rally had begun, with nine trading days left in the year.&nbsp;<blockquote>“Expectations for an up market in the new year are the highest in 4 years. Ending the year at new highs is back on the table, as investors position themselves for a strong start to 2026.”</blockquote><h2 class="st-heading-2">Rate Cuts, AI Surge Likely To Be Market Theme</h2>The fears of the length of the bull market are ill-founded. According to a graphic shared by First Trust, the average bull market lasts 4.3 years and returns 151.4%. By this historical norm, the current market is still young: it is only a little over three years old, and the gain has been 89%.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_19_at_3_17_26_AM_png_5713fd7ac4.webp" alt="Screenshot 2025-12-19 at 3.17.26 AM.png">Source: First TrustStrategists pin their hopes on strong profit growth and a resilient economy to support continued market gains next year. Zaccarelli sees further gains:<blockquote>“While next year will undoubtedly bring new challenges, heading into the end of the year, there should be room for the market to move higher as corporate profits are increasing, the GDP is growing and inflation (for now) remains in check.”</blockquote>In its 2026 outlook report, Morgan Stanley said it is overweight on U.S. equities due to resilient growth. The firm prefers U.S. large-caps despite market talk of the tech rally broadening as interest rates drop. It also looks for selective exposure to mid-cap stocks.<blockquote>“Economic conditions and market performance in 2026 may prove to be more U-shaped than K. The trough likely occurred in 2025, partially masked by stronger equity performance, with notably narrow leadership.”</blockquote>Despite the doom-and-gloom talk about artificial intelligence (AI), the technology is expected to boost the economy through increased spending and productivity gains.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, was ‘bearish’ as of early Friday. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> also elicited a ‘bearish’ sentiment, while retail traders were ‘extremely bearish’ on the&nbsp;<a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF (IWM)</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-had-ev-spotlight-this-year-this-chinese-rival-took-the-trophy/cLegpsgREAy">Tesla Stock Had The EV Spotlight This Year — This Chinese Rival Took The Trophy</a>

Night view of the illuminated exterior of New York Stock Exchange with a big American flag from the front facade, pictured in November 2024 in NYC, USA.

Soft Inflation Ushers Santa Onto Wall Street — Will Seasonal Trends Follow?

 Inflation eased, and yields fell, lifting stocks, but stretched valuations and cautious retail sentiment temper optimism.

<ul class="summary-bullets"><li>The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution.</li><li>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech.</li><li>The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders.</li></ul>Taiwan-based biotechnology company YD Bio (YDES) said on Monday that it has reached a set of milestones that together mark its commercial entry into U.S. eye care.Following the announcement, shares of the firm traded 7% higher at the time of writing. &nbsp;The Taiwan-based company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ydesgroup.com/pressreleases/detail/23e04a99-0c62-4d1e-bd0e-ea782181d34c">said</a> that Exovisse Contact Lenses have obtained U.S. Food and Drug Administration clearance through its partner, 3D Global Biotech, confirming that the lenses are substantially equivalent to an already marketed device and can be sold in the U.S.The company also said that its Exovisse Artificial Tears have been developed in compliance with FDA mandates permitting nationwide over‑the‑counter distribution for eye hydration and dry eye comfort without individual FDA premarket approval.<h2 class="st-heading-2">Future Plans</h2>YD Bio now plans to conduct a small clinical trial in Taiwan to evaluate dry eye disease in collaboration with 3D Global Biotech and Taiwan-based contract research organization YC Biotech.The company is also advancing LSC Exosome Therapeutics through its collaboration with 3D Global Biotech for retinal and macular disorders. LSC exosome therapeutics refers to the use of exosomes derived from limbal stem cells (LSCs) for therapeutic purposes, particularly for conditions affecting the eye, like dry eye syndrome.The company said that it has enrolled its limbal stem cells and limbal stem cell exosomes in the FDA Drug Master File, establishing documentation to support future therapeutic development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around YDES stayed within the ‘neutral’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:586/61;" src="data:image/png;base64,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" width="586" height="61" alt="YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>YDES’s Sentiment Meter and Message Volume as of 12:37 p.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/YDES">YDES stock</a> is down by 20% this year and by about 22% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-goes-short-on-capircor-therapeutics/cL5bQHUREQS">‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

YD Bio Stock Rises On Entry Into US Eye Care Segment

The Taiwan-based company said that Exovisse Contact Lenses have obtained the U.S. Food and Drug Administration’s clearance through its partner 3D Global Biotech.

<ul class="summary-bullets"><li>The broader market has taken a beating since hitting fresh peaks in late October, with AI skepticism largely to blame.</li><li>Nebius announced a deal with Microsoft in early September to deliver dedicated capacity to the software giant from its new Vineland, New Jersey data center.</li><li>Retail has chosen to ignore the negativity and see the dip as a buying opportunity.</li></ul>Artificial intelligence (AI) infrastructure company Nebius Group N.V. (NBIS) “pain is not over,” according to CNBC Mad Money host Jim Cramer.&nbsp;<a href="https://stocktwits.com/symbol/NBIS">Nebius stock</a> is in deep correction territory, having declined about 40% since it hit a record high (intraday) of $141.10, set on Oct. 10.The broader market has taken a beating since hitting fresh peaks in late October, with AI skepticism largely to blame. Bearish commentary from high-profile investors such as Michael Burry has also heightened the panic.&nbsp;<h2 class="st-heading-2">Deals Raise Red Flag</h2>In a post on X, Cramer said, “I can't believe the capital destruction for press releases on deals and nothing else….NBIS, NJ, Microsoft.”&nbsp; The stock picker is referring to the multi-billion-dollar deal Nebius announced with Microsoft (MSFT) in early September to deliver dedicated capacity to the software giant from its new Vineland, New Jersey data center.When the deal was announced, Nebius' stock got a shot in the arm, jumping 49% in a single session.&nbsp; “In other words, stay away,” said Cramer.<h2 class="st-heading-2">AI Pessimism Abounds</h2>The main point of contention for skeptics is the AI bubble that has been building since late 2022, when OpenAI launched its large language model, ChatGPT. They question the logic of AI names, big and small, splurging investment dollars on infrastructure buildout, fearing the returns may not be commensurate&nbsp;with the investment.Of late, concerns of hyperscalers using accounting gimmicks to boost profitability have heightened. Burry, for one, called out Meta and Oracle in particular. After Nvidia reported stellar quarterly results, Burry questioned the Jensen Huang-led company’s stock-based compensation accounting.AI bears also point out the circular deals in the space, such as those involving Nvidia, in which customers buy computing power from the company, and the chipmaker, in turn, invests in them.<h2 class="st-heading-2">What Retail Feels About Nebius Stock</h2>On Stocktwits, retail sentiment toward the stock remained ‘bullish’ as of early Friday, and the message volume on the stream remained ‘high.’Retail sees the pullback as a buying opportunity. “Sold my previous position last night at 99.85 and regretted it. What a gift it’s back in the low 80s today,” a user chimed in.<stembedurl>https://stocktwits.com/ISmokeCigs/message/637027503</stembedurl>Another user shrugged the Nebius sell-off as a “market-driven” event. “The good thing is there is no Nebius-specific issue; if the market bounces, we will bounce,” they said.<stembedurl>https://stocktwits.com/Gemhunter6474/message/637011328</stembedurl>Nebius' stock is up over 200% despite the recent volatility.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-nasdaq-100-futures-tick-higher-but-fear-rules/cLPMOKfREaH">Dow, S&amp;P 500 Futures Tick Higher, But Fear Rules Amid Worst November Since 2008 — Strategists Split On Buying The Dip</a>

In this photo illustration, the Nebius logo is seen displayed on a smartphone screen. 

Jim Cramer Can’t Believe Nebius’ Capital Destruction As Stock Trades Deep In Bear Zone: ‘Pain Is Not Over’

Nebius stock is up over 200% despite the recent volatility, but it has shed 40% since its October highs.

Fidelity Commonwealth Trust - Fidelity Nasdaq Composite Index ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ONEQ
Fidelity Nasdaq Composite Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ONEQ News

ONEQFidelity Nasdaq Composite Index ETF